HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Cilta-cel Garners More Positive Data in Early and Late Relapsed Multiple Myeloma Treatment

Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.

“In cohort B, we enrolled patients who have been treated with the standard of care frontline therapy, such as bone marrow transplant, or... standard cocktail therapies... but unfortunately, these patients relapsed within 12 months of that initiation of therapy. These patients havevery poor prognosis because if a patient relapses so early after frontline therapy, the median survival is only about 26 months, unfortunately. So, this patient population needs a new therapy.”

New data on the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Legend Biotech), approved for the fifth line treatment of multiple myeloma, were presented in 3 posters at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana.

CGTLive spoke with Ying Huang, chief executive officer, Legend Biotech, to learn more about the new data from the CARTITUDE-2 (NCT04133636) and CARTIFAN-1 (NCT03758417) studies. He discussed the positive data seen in second-line treatment of patients with early relapsed disease as well as longer follow-up data in patients treated in the fifth line.

Click here to read more coverage of the ASH 2022 meeting.

REFERENCES
1. Van De Donk N, Agha M, Cohen A, et al. Ciltacabtageneautoleucel (cilta-cel), a BCMA-directed CAR T cell therapy, in patients with multiple myeloma (MM) and early relapsed after initial therapy: CARTITUDE-2 cohort B 18-month follow-up. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana. Poster #3354
2. Munshi N, Palva B, Martin T, et al. Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana. Poster #2030
3. Cohen A, Mateos MV, Cohen Y, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to non-cellular anti-BCMA immunotherapy. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana. Poster #2028